LARIMAR THERAPEUTICS, INC.

LRMR ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $85.4M $33.2M $26.7M $26.8M $70.1M $68.1M $1.0M $49.3M
Accounts Receivable
Inventory
Total Current Assets $142.0M $195.3M $90.2M $120.7M $72.2M $98.0M $4.8M $121.3M
Property, Plant & Equipment $622.0K $881.0K $684.0K $831.0K $1.0M $1.0M $274.0K $375.0K
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $145.8M $200.2M $95.9M $126.4M $78.7M $104.7M $5.2M $121.8M
Liabilities
Accounts Payable $5.2M $2.4M $1.3M $1.7M $1.7M $2.6M $3.5M $3.6M
Total Current Liabilities $64.8M $24.4M $9.5M $10.7M $8.8M $9.0M $5.9M $13.3M
Long-Term Debt $14.5M $20.0M
Total Liabilities $67.8M $28.4M $14.2M $15.5M $14.3M $15.0M $5.9M $28.5M
Stockholders' Equity
Retained Earnings $-434.8M $-269.2M $-188.6M $-151.6M $-116.3M $-65.6M $-23.1M $-350.9M
Total Stockholders' Equity $78.1M $171.8M $81.7M $110.9M $64.4M $89.7M $-694.0K $2.9M
← Newer Page 1 of 2 Older →